Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.410
+0.090 (6.82%)
At close: Apr 6, 2026, 4:00 PM EDT
1.400
-0.010 (-0.71%)
Pre-market: Apr 7, 2026, 4:00 AM EDT

Marker Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-12.16-10.73-16.47-29.93-41.88
Depreciation & Amortization
---3.683.16
Stock-Based Compensation
0.540.250.865.345.96
Other Adjustments
----0.25-
Change in Receivables
0.98-1.321.37-2.41
Changes in Accounts Payable
-0.450.01-0.72-4.34.14
Changes in Unearned Revenue
0.97--1.351.15
Changes in Other Operating Activities
-1.890.892.19-0.46-0.82
Operating Cash Flow
-12.01-10.91-16.44-26.97-27.28
Capital Expenditures
----4.95-3.13
Investing Cash Flow
--18.66-4.95-3.13
Issuance of Common Stock
9.8614.991.110.252.56
Net Common Stock Issued (Repurchased)
9.8614.991.110.252.56
Financing Cash Flow
9.8614.991.110.252.56
Net Cash Flow
-2.154.083.33-31.7222.14
Free Cash Flow
-12.01-10.91-16.44-31.92-30.41
FCF Margin
-338.74%-165.53%-496.51%-354.10%-2449.11%
Free Cash Flow Per Share
-0.78-1.21-1.87-3.82-3.97
Levered Free Cash Flow
-13.53-9.84-6.76-34.61-37.38
Unlevered Free Cash Flow
-14.24-10.28-13.11-34.62-34.97
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q